Harmony Biosciences Holdings (Nasdaq:HRMY) - Aktienkurs, Nachrichten und Analyse

HRMY Aktienübersicht

HRMY grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	4/6
Künftiges Wachstum	5/6
Vergangene Leistung	3/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

85.8% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 32.82% pro Jahr

Risikoanalyse

Die Gewinnspannen (18%) sind niedriger als im Vorjahr (27.8%)

Harmony Biosciences Holdings, Inc. Wettbewerber

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$2.2b

Supernus Pharmaceuticals

NasdaqGM:SUPN

US$2.0b

Collegium Pharmaceutical

NasdaqGS:COLL

US$966.2m

Endo

OTCPK:NDOI

US$1.9b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Harmony Biosciences Holdings
Historische Aktienkurse
Aktueller Aktienkurs	US$34.07
52-Wochen-Hoch	US$41.61
52-Wochen-Tief	US$28.14
Beta	0.77
11 Monat Veränderung	-1.25%
3 Monate Veränderung	-5.77%
1 Jahr Veränderung	17.36%
33 Jahre Veränderung	-9.27%
5 Jahre Veränderung	n/a
Veränderung seit IPO	-7.94%

Aktuelle Nachrichten und Updates

Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points

Nov 11

Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next

Oct 31

Is Harmony Biosciences Holdings (NASDAQ:HRMY) Using Too Much Debt?

Oct 30

Recent updates

Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points

Nov 11

Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next

Oct 31

Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 03

These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely

Apr 04

Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings

Feb 09

Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Mar 21

Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?

Dec 01

Harmony Biosciences: In Harmony

Sep 23

We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease

Aug 05

Harmony Biosciences Non-GAAP EPS of $0.57 misses by $0.06, revenue of $107M beats by $6.25M

Aug 02

Harmony Biosciences: Steady Revenue Generator Looking For A Future

May 26

Aktionärsrenditen

	HRMY	US Pharmaceuticals	US Markt
7D	2.6%	1.6%	2.2%
1Y	17.4%	9.9%	31.6%

Rendite im Vergleich zur Industrie: HRMY übertraf die Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 9.9 erzielte.

Rendite vs. Markt: HRMY hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 31.6 erzielte.

Preisvolatilität

Is HRMY's price volatile compared to industry and market?
HRMY volatility
HRMY Average Weekly Movement	8.7%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: HRMY hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: HRMYDie wöchentliche Volatilität (9%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2017	246	Jeffrey Dayno	www.harmonybiosciences.com

Harmony Biosciences Holdings, Inc. ist ein pharmazeutisches Unternehmen im Entwicklungsstadium, das sich auf die Entwicklung und Vermarktung von Therapien für Patienten mit seltenen und anderen neurologischen Krankheiten in den Vereinigten Staaten konzentriert. Das Unternehmen bietet WAKIX (Pitolisant) an, ein Molekül mit einem neuartigen Wirkmechanismus zur Behandlung von exzessiver Tagesschläfrigkeit bei erwachsenen Patienten mit Narkolepsie. Außerdem bietet es HBS-102 an, einen Melanin-konzentrierenden Hormonrezeptor 1 für MCH-Neuronen.

Harmony Biosciences Holdings, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Harmony Biosciences Holdings im Vergleich zum Marktanteil des Unternehmens?
HRMY grundlegende Statistiken
Marktanteil	US$1.94b
Gewinn(TTM)	US$122.63m
Umsatz(TTM)	US$681.88m

15.8x

Kurs-Gewinn-Verhältnis

2.8x

Kurs-Umsatz-Verhältnis

Ist HRMY zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
HRMY Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$681.88m
Kosten der Einnahmen	US$145.56m
Bruttogewinn	US$536.32m
Sonstige Ausgaben	US$413.70m
Umsatz	US$122.63m

Zuletzt gemeldete Gewinne

Sep 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	2.15
Bruttomarge	78.65%
Nettogewinnspanne	17.98%
Schulden/Eigenkapital-Verhältnis	30.6%

Wie hat sich HRMY auf lange Sicht entwickelt?

Historische Performance und Vergleiche

HRMY Aktienübersicht

Belohnungen

Risikoanalyse

Harmony Biosciences Holdings, Inc. Wettbewerber

NasdaqGS:AMPH

US$2.2b

NasdaqGM:SUPN

US$2.0b

NasdaqGS:COLL

US$966.2m

OTCPK:NDOI

US$1.9b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points

Harmony Biosciences Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $248 million.

Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next

Harmony Biosciences Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $248 million.

Harmony Biosciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $286 million.

Is Harmony Biosciences Holdings (NASDAQ:HRMY) Using Too Much Debt?

Recent updates

Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points

Harmony Biosciences Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $248 million.

Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next

Harmony Biosciences Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $248 million.

Harmony Biosciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $286 million.

Is Harmony Biosciences Holdings (NASDAQ:HRMY) Using Too Much Debt?

Harmony Biosciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $286 million.

Harmony Biosciences Holdings, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Many Still Looking Away From Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Harmony Biosciences: Advancing An Expanded Pipeline

Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024

Harmony Biosciences Holdings, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet

Harmony Biosciences Holdings, Inc. Announces U.S. Food & Drug Administration (FDA) Action Deny the Citized Petition for WAKIX®? (PITOLSIANT)

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX (Pitolisant) in Pediatric Patients with Narcolepsy

Harmony Biosciences Holdings, Inc. Reaffirms Sales Guidance for the Year 2024

Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

HARMONY Biosciences Presents Positive Data for Pitolisant in the Treatment of Excessive Daytime Sleepiness and FATIGUE in Myotonic Dystrophy Type 1

Consensus EPS estimates fall by 21%

Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations

Harmony Biosciences Holdings, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Harmony Biosciences Holdings, Inc., Annual General Meeting, May 29, 2024

These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely

Executive VP exercised options and sold US$269k worth of stock

Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) of Pitolisant in Patients with Prader-Willi Syndrome

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Consensus EPS estimates fall by 11%

Full year 2023 earnings: EPS misses analyst expectations

U.S. Food and Drug Administration Grants Priority Review to Harmony Biosciences' Application for WAKIX® (pitolisant) in Pediatric Narcolepsy

Harmony Biosciences Holdings, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings

Harmony Biosciences Holdings, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year 2023 and for the Year 2024

Harmony Biosciences Holdings, Inc. Announces Positive Topline Data from Phase 2 Signal Detection Study Evaluating Pitolisant in Adult Patients with Myotonic Dystrophy Type 1

Harmony Biosciences Holdings, Inc. Appoints Peter Anastasiou as Class III Director and Member of the Compensation Committee of the Board

Harmony Biosciences Holdings, Inc. Appoints Peter Anastasiou to its Board of Directors

Investor sentiment improves as stock rises 26%

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) announces an Equity Buyback for $200 million worth of its shares.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Harmony Biosciences Showcases the Newest Patients At the Heart and Progress At the Heart Award Recipients

Harmony Biosciences Holdings, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Harmony Biosciences Holdings, Inc. Announces Topline Data from Phase 3 Intune Study Evaluating Pitolisant in Patients with Idiopathic Hypersomnia

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 35%

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) announces an Equity Buyback for $125 million worth of its shares.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Harmony Biosciences Holdings, Inc. Announces Plans to Initiate Phase 3 Registration Study of Pitolisant in Prader-Willi Syndrome

Harmony Biosciences Holdings, Inc. Completes Enrollment of Phase 3 Registrational Intune Study in Idiopathic Hypersomnia

Harmony Biosciences Holdings, Inc. to Present New Wanix (Pitolisant) Safety and Efficacy Data

Harmony Biosciences Holdings, Inc. Appoints Kumar Budur as Chief Medical Officer

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.4% to US$59.89

Executive VP & CFO exercised options and sold US$514k worth of stock

Investor sentiment deteriorates as stock falls 27%

Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Full year 2022 earnings: EPS exceeds analyst expectations

Harmony Biosciences Holdings, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Erträge & Einnahmen